BCRX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

150.26M

+14.24%

0.041

-159.23%

155.45M

+6.82%

0.039

-129.67%

Estimates Revision

The market is revising Downward the revenue expectations for BioCryst Pharmaceuticals, Inc. (BCRX) for FY2025, with the revenue forecasts being adjusted by -1.23% over the past three months. During the same period, the stock price has changed by 8.90%.

Revenue Estimates for FY2025

Revise Downward

-1.23%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-45.99%

In Past 3 Month

Stock Price

Go Up

+8.90%

In Past 3 Month

11 Analyst Rating

Wall Street analysts forecast BCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCRX is 19.27 USD with a low forecast of 8.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

8.00

Averages

19.27

High

30.00

Current: 0.000

Low

8.00

Averages

19.27

High

30.00

BTIG

initiated

$28

2026-01-08

New

Reason

BTIG

Price Target

$28

2026-01-08

New

initiated

Reason

BTIG initiated coverage of Bicara Therapeutics with a Buy rating and $28 price target. Bicara is a clinical stage biotechnology company advancing ficerafusp alfa for head and neck squamous cell carcinoma and other solid tumors, the analyst tells investors in a research note. The firm believes the Phase 1b data for ficera plus pembrolizumab shows clinically differentiated duration of response and survival data compared to the standard of care. It believes the HNSCC market is "capable of supporting multiple players."

H.C. Wainwright

Buy

maintain

$30 -> $32

2025-12-15

Reason

H.C. Wainwright

Price Target

$30 -> $32

2025-12-15

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on BioCryst to $32 from $30 and keeps a Buy rating on the shares. The firm cites the approval of Orladeyo in the pediatric patient population for the target bump. Orladeyo is the first and only targeted oral prophylactic therapy approved for use in patients ages two to 12 with hereditary angioedema, the analyst tells investors in a research note.

Citizens JMP

Jonathan Wolleben

Outperform

downgrade

$27 -> $25

2025-11-05

Reason

Citizens JMP

Jonathan Wolleben

Price Target

$27 -> $25

2025-11-05

downgrade

Outperform

Reason

Citizens JMP analyst Jonathan Wolleben lowered the firm's price target on BioCryst to $25 from $27 and keeps an Outperform rating on the shares following the Q3 earnings report. The firm likes the continued positive trajectory of Orladeyo sales fueled by a growing prescriber base, consistent high patient retention, and strong reimbursement dynamics, the analyst tells investors in a research note. BioCryst is well-positioned for growth, with Orladeyo sales continuing to move higher, pipeline expansion with the strategic addition of navenibart, and potentially de-risking Netherton syndrome data on the horizon, the firm states.

Barclays

Equal Weight

downgrade

$11 -> $9

2025-11-04

Reason

Barclays

Price Target

$11 -> $9

2025-11-04

downgrade

Equal Weight

Reason

Barclays lowered the firm's price target on BioCryst to $9 from $11 and keeps an Equal Weight rating on the shares. The company reported an inline Q3 for Orladeyo with narrowed guidance, the analyst tells investors in a research note.

Cantor Fitzgerald

Steve Seedhouse

Overweight

maintain

$24 -> $26

2025-10-15

Reason

Cantor Fitzgerald

Steve Seedhouse

Price Target

$24 -> $26

2025-10-15

maintain

Overweight

Reason

Cantor Fitzgerald analyst Steve Seedhouse raised the firm's price target on BioCryst (BCRX) to $26 from $24 and keeps an Overweight rating on the shares. BioCryst is buying top pick Astria Therapeutics (ATXS) for $700M in enterprise value, and the deal is a "terrific" value for BioCryst, even before accounting for essentially total SG&A synergy, and it allows BioCryst to protect and extend its core HAE commercial leadership position through navenibart's loss of exclusivity in 2042, the analyst tells investors in a research note.

Jefferies

Buy

Hold

downgrade

$30 -> $13

2025-10-14

Reason

Jefferies

Price Target

$30 -> $13

2025-10-14

downgrade

Buy

Hold

Reason

Jefferies downgraded Astria Therapeutics to Hold from Buy with a price target of $13, down from $30, after the company reached an agreement to be acquired by BioCryst (BCRX) for cash and stock at an implied value of $13 per share, or $700M. The firm expects the deal to close on time in Q1 of 2026.

Valuation Metrics

The current forward P/E ratio for BioCryst Pharmaceuticals Inc (BCRX.O) is 31.75, compared to its 5-year average forward P/E of -32.08. For a more detailed relative valuation and DCF analysis to assess BioCryst Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-32.08

Current PE

31.75

Overvalued PE

70.49

Undervalued PE

-134.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.74

Current EV/EBITDA

22.73

Overvalued EV/EBITDA

54.92

Undervalued EV/EBITDA

-70.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.41

Current PS

2.48

Overvalued PS

11.31

Undervalued PS

1.50

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 1842.59% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 1842.59% over the last month.

Sold

Bought

BCRX News & Events

Events Timeline

No data

News

8.5

01-07PRnewswire

Astria Therapeutics to be Sold to BioCryst for $8.55 per Share

5.0

01-06Globenewswire

BioCryst Grants 18,300 RSUs to New Employee as Inducement

1.0

01-06Globenewswire

BioCryst to Present at J.P. Morgan Healthcare Conference on January 12, 2026

People Also Watch

Frequently Asked Questions

What is BioCryst Pharmaceuticals Inc (BCRX) stock price today?

The current price of BCRX is 7.895 USD — it has increased 3.61 % in the last trading day.

What is BioCryst Pharmaceuticals Inc (BCRX)'s business?

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

What is the price predicton of BCRX Stock?

What is BioCryst Pharmaceuticals Inc (BCRX)'s revenue for the last quarter?

BioCryst Pharmaceuticals Inc revenue for the last quarter amounts to 159.40M USD, increased 36.14 % YoY.

What is BioCryst Pharmaceuticals Inc (BCRX)'s earnings per share (EPS) for the last quarter?

BioCryst Pharmaceuticals Inc. EPS for the last quarter amounts to 0.06 USD, decreased -185.71 % YoY.

What changes have occurred in the market's expectations for BioCryst Pharmaceuticals Inc (BCRX)'s fundamentals?

How many employees does BioCryst Pharmaceuticals Inc (BCRX). have?

BioCryst Pharmaceuticals Inc (BCRX) has 580 emplpoyees as of January 09 2026.

What is BioCryst Pharmaceuticals Inc (BCRX) market cap?

Today BCRX has the market capitalization of 1.61B USD.